Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sachin Pai, MD
Corcept Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
117 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 393
CABA, Buenos Aires, Argentina
- Site 381
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
- Site 395
Córdoba, Córdoba Province, Argentina
- Site 401
Córdoba, Córdoba Province, Argentina
- Site 415
Córdoba, Córdoba Province, Argentina
- Site 404
Mendoza, Mendoza Province, Argentina
- Site 391
Rosario, Santa Fe Province, Argentina
- Site 412
Rosario, Santa Fe Province, Argentina
- Site 426
St Leonards, New South Wales, Australia
- Site 417
Benowa, Queensland, Australia
- Site 414
Melbourne, Victoria, Australia
- Site 419
Melbourne, Victoria, Australia
- Site 328
Aalst, Belgium
- Site 109
Brussels, Belgium
- Site 326
Charleroi, Belgium
- Site 325
Hasselt, Belgium
- Site 108
Leuven, Belgium
- Site 327
Liège, Belgium
- Site 424
Brasília, Brasília - DF, Brazil
- Site 382
Fortaleza, Ceará, Brazil
- Site 384
Salvador, Estado de Bahia, Brazil
- Site 383
Belo Horizonte, Minas Gerais, Brazil
- Site 390
Natal, Rio Grande do Norte, Brazil
- Site 413
São Paulo, São Paulo, Brazil
- Site 421
Porto Alegre, Brazil
- Site 380
Rio de Janeiro, Brazil
- Site 001
São Paulo, Brazil
- Site 374
São Paulo, Brazil
- Site 376
São Paulo, Brazil
- Site 389
São Paulo, Brazil
- Site 413
São Paulo, Brazil
- Site 117
Toronto, Ontario, Canada
- Site 273
Montreal, Quebec, Canada
- Site 306
Lille, France
- Site 347
Montpellier, France
- Site 307
Nancy, France
- Site 310
Nice, France
- Site 289
Paris, France
- Site 323
Plérin, France
- Site 322
Budapest, Hungary
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Jun 2022
- Primary completion
- 24 Mar 2025
- Completion
- 31 Mar 2026
- Last update posted
- 16 Apr 2025
- Registered enrollment
- 381
- Registry id
- NCT05257408
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.